KSG Investigates Bravelle the Fertility Injection by Ferring Pharmaceuticals

Kohn, Swift & Graf, P.C. is investigating claims for a class action lawsuit against Ferring Pharmaceuticals, Inc. for Bravelle©, the brand name version of urofollitropin.

The drug is designed to treat infertility in women. By stimulating egg maturation and multiple follicular development, it helps women—capable of producing and releasing eggs—become pregnant; it is frequently used during assisted reproductive procedures like in vitro fertilization (“IVF”), an expensive procedure that often costs $15,000 to $20,000 before medication. Most insurances do not cover IVF and other expenses incurred by assisted reproductive technology. Despite the high out-out-pocket expenses, more than American 85,000 women undergo the IVF procedure every year.

The financial risk did not pay off for women who purchased Bravelle between March 2014 and October 2015. Ferring Pharmaceuticals has admitted that certain lots produced during this period contained lower than normal dosage of an ingredient, follicle stimulating hormones (“FSH”).

Although Ferring Pharmaceuticals, Inc. has voluntarily recalled the defective Bravelle and offered reimbursement for the price of Bravelle to affected consumers can, this is not an adequate reimbursement for many purchasers of the defective products. As stated earlier, there are numerous other out-of-pocket expenditures during the process of fertility treatments. Had these consumers known about the defective nature of Bravelle, they would not have spent thousands of dollars for associated with fertility treatments such as medical facility procedure fees, pre-implantation fees, etc. Many women, who failed to become pregnant with the defective Bravelle, cannot afford another IVF procedure without a higher reimbursement from Ferring Pharmaceuticals, Inc.

If you, or someone you know, has purchased Bravelle between March 2014 and October 2015, please contact us to discuss your potential claim. All initial consultations are free of charge.

Kohn, Swift & Graf is a national leader in class actions, including complex consumer litigation. With experienced attorneys and a competent support staff, our firm strives to provide the highest quality of service to our clients. We treat each case with careful attention to ensure that consumers get the justice they deserve. KSG is centrally located in Philadelphia, PA.